This article is more than 5 years old. Information may no longer be current.

Diplomat Pharmacy to distribute Cosentyx for adults with plaque psoriasis

Diplomat Pharmacy has been chosen by the Novartis limited-distribution panel to distribute Cosentyx as treatment for adults with moderate-to-severe plaque psoriasis.

Cosentyx (secukinumab, Novartis) was approved by the FDA in January as subcutaneous treatment for plaque psoriasis in patients eligible for systemic therapy, phototherapy or a combination of the two, according to a press release. Secukinumab binds to interleukin (IL)-17A, to prevent the IL-17A protein from binding to its receptor and inhibiting its ability to trigger the inflammation that results in plaque psoriasis, the release stated.

Flint, Mich.-based Diplomat serves patients and physicians in all 50 states and focuses on medication management programs for people with complex chronic diseases, according to the release.

Reference: www.diplomat.is.